Anti-Anterior gradient 3 [AGR3.2]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-Anterior gradient 3 [AGR3.2]
• Clone: AGR3.2
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Molecular weight: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.
• Reactivity: Human
• Host: Mouse
• Description: Antibody created to detect the endogenous AGR3 protein (with weaker affinity than the Mouse anti- Anterior gradient 3 monoclonal antibody (AGR3.1]). Binding specificity: human AGR3 protein. Epitope QYSQALKKV (determined using pepscan)
• Immunogen: Purified human AGR3 protein
• Isotype: IgG1 kappa
• Production details: B cell donor: Splenocytes from mouse immunised with purified AGR3 protein, fusion partner: SP2

Target Details

• Target: Anterior gradient 3
• Molecular weight: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.
• Target background: AGR3 (Anterior Gradient 3) is a human homologue of the XAG-2 protein expressed in Xenopus laevis, which was identified in a study analyzing mRNA expression in ER-positive breast cancer-derived cell lines. The coding sequence of the AGR3 protein is located on the chromosome at position 7p21. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor ?)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers.
• Epitope sequence: QYSQALKKV of Anterior gradient 3

Handling

• Format: Liquid